↓ Skip to main content

Atypical Antipsychotic Drugs in the Treatment of Parkinson’s Disease

Overview of attention for article published in Journal of Pharmacy Practice, November 2011
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (85th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

twitter
4 X users
patent
1 patent
facebook
1 Facebook page
guideline
1 clinical guideline source

Readers on

mendeley
81 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Article details
Title
Atypical Antipsychotic Drugs in the Treatment of Parkinson’s Disease
Published in
Journal of Pharmacy Practice, November 2011
DOI 10.1177/0897190011426556
Pubmed ID
Authors
Abstract

Parkinson's disease (PD) patients often develop psychotic symptoms that severely affect quality of life and limit the use of medications to ameliorate motor symptoms. Psychotic symptoms are a major cause for nursing home placement. While these symptoms do not always require treatment, they often do but antipsychotic drugs all share the common pharmacological mechanism of blocking dopamine D2 receptors which may worsen motor problems in this very vulnerable population. Double blind, placebo controlled trials (DBPCT) have shown that clozapine is effective at controlling the psychotic symptoms at doses far below those used in schizophrenia, without worsening motor function, even improving tremor. DBPCT have demonstrated that olanzapine worsens motor function without improving psychosis. Quetiapine has been shown in DBPCT to be free of motor side effects in PD patients but not effective, whereas many open label studies have indicated that quetiapine is effective. The other atypical have been the subjects of conflicting open label reports. The effects of the atypicals in PD psychosis is reviewed.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 81 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
United Kingdom 1 1%
Spain 1 1%
Chile 1 1%
Belgium 1 1%
Unknown 77 95%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Researcher 14 17%
Other 12 15%
Student > Bachelor 9 11%
Student > Master 8 10%
Student > Ph. D. Student 7 9%
Other 16 20%
Unknown 15 19%
Readers by discipline
Readers by discipline Count As %
Medicine and Dentistry 32 40%
Neuroscience 9 11%
Psychology 8 10%
Nursing and Health Professions 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 9 11%
Unknown 16 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2026.
All research outputs
#5,943,720
of 34,795,682 outputs
Outputs from Journal of Pharmacy Practice
#160
of 1,161 outputs
Outputs of similar age
#43,003
of 305,181 outputs
Outputs of similar age from Journal of Pharmacy Practice
#6
of 21 outputs
Altmetric has tracked 34,795,682 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,161 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 305,181 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.